U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H19N3O5S
Molecular Weight 401.4381
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXACILLIN

SMILES

Cc1c(c(-c2ccccc2)no1)C(=N[C@]3([H])C(=O)N4[C@@]([H])(C(=O)O)C(C)(C)S[C@]34[H])O

InChI

InChIKey=UWYHMGVUTGAWSP-JKIFEVAISA-N
InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H19N3O5S
Molecular Weight 401.4381
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050640s017lbl.pdf

Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Oxacillin results from the inhibition of cell wall synthesis and is mediated through Oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Oxacillin interferes with an autolysin inhibitor. Oxacillin is used in the treatment of resistant staphylococci infections. Oxacillin sodium was marketed under the trade name Bactocill.

CNS Activity

Curator's Comment:: CSF penetration is poor but enhanced by meningeal inflammation

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Oxacillin

Approved Use

Oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug.

Launch Date

3.9830401E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
43 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OXACILLIN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
125.9 mg × h/L
30 mg/kg bw single, intravenous
dose: 30 mg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OXACILLIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.42 h
30 mg/kg bw single, intravenous
dose: 30 mg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OXACILLIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
25 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OXACILLIN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6%
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OXACILLIN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
175 mg/kg/day 1 times / day multiple, intravenous
Studied dose
Dose: 175 mg/kg/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 175 mg/kg/day, 1 times / day
Sources:
unhealthy, mean age 4.96 years
n = 8
Health Status: unhealthy
Condition: sternal osteomyelitis
Age Group: mean age 4.96 years
Sex: M+F
Population Size: 8
Sources:
Other AEs: Elevated liver enzymes...
Other AEs:
Elevated liver enzymes (12.5%)
Sources:
175 mg/kg/day 1 times / day multiple, intravenous
Studied dose
Dose: 175 mg/kg/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 175 mg/kg/day, 1 times / day
Sources:
unhealthy, mean age 4.96 years
n = 8
Health Status: unhealthy
Condition: submandibular adenitis
Age Group: mean age 4.96 years
Sex: M+F
Population Size: 8
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (12.5%)
Sources:
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Other AEs: Nausea, Headache...
Other AEs:
Nausea (grade 1-2, 5.7%)
Headache (grade 1-2, 3.8%)
Vomiting (grade 1-2, 1.9%)
Hypertension (grade 1-2, 0.2%)
Diarrhea (grade 1-2, 2.9%)
Pain localized (grade 1-2, 0.7%)
Dyspepsia (grade 1-2, 1.7%)
Insomnia (grade 1-2, 2.1%)
Dizziness (grade 1-2, 0.7%)
Abdominal pain (grade 1-2, 1.2%)
Constipation (grade 1-2, 3.1%)
Pruritus (grade 1-2, 2.1%)
Fever (grade 1-2, 2.6%)
Sources:
12 g/day 1 times / day multiple, intravenous
Studied dose
Dose: 12 g/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g/day, 1 times / day
Sources:
unhealthy, mean age 51 years
n = 34
Health Status: unhealthy
Condition: complicated bacteremia
Age Group: mean age 51 years
Sex: M+F
Population Size: 34
Sources:
Disc. AE: Transaminases increased, Leukopenia...
Other AEs: Rash, Transaminases increased...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (11.8%)
Leukopenia (3%)
Blood sodium decreased (3%)
Rash (3%)
Other AEs:
Rash (3%)
Transaminases increased (18%)
Creatinine serum increased (3%)
Leukopenia (3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Elevated liver enzymes 12.5%
175 mg/kg/day 1 times / day multiple, intravenous
Studied dose
Dose: 175 mg/kg/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 175 mg/kg/day, 1 times / day
Sources:
unhealthy, mean age 4.96 years
n = 8
Health Status: unhealthy
Condition: sternal osteomyelitis
Age Group: mean age 4.96 years
Sex: M+F
Population Size: 8
Sources:
Neutropenia 12.5%
175 mg/kg/day 1 times / day multiple, intravenous
Studied dose
Dose: 175 mg/kg/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 175 mg/kg/day, 1 times / day
Sources:
unhealthy, mean age 4.96 years
n = 8
Health Status: unhealthy
Condition: submandibular adenitis
Age Group: mean age 4.96 years
Sex: M+F
Population Size: 8
Sources:
Hypertension grade 1-2, 0.2%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Dizziness grade 1-2, 0.7%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Pain localized grade 1-2, 0.7%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Abdominal pain grade 1-2, 1.2%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Dyspepsia grade 1-2, 1.7%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Vomiting grade 1-2, 1.9%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Insomnia grade 1-2, 2.1%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Pruritus grade 1-2, 2.1%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Fever grade 1-2, 2.6%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Diarrhea grade 1-2, 2.9%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Constipation grade 1-2, 3.1%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Headache grade 1-2, 3.8%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Nausea grade 1-2, 5.7%
2 g 4 times / day multiple, intravenous
Studied dose
Dose: 2 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 4 times / day
Co-administed with::
dicloxacillin(500 mg orally; 4 per day)
Sources:
unhealthy, mean age 49.2 years
n = 419
Health Status: unhealthy
Condition: complicated skin and soft tissue infections
Age Group: mean age 49.2 years
Sex: M+F
Population Size: 419
Sources:
Transaminases increased 11.8%
Disc. AE
12 g/day 1 times / day multiple, intravenous
Studied dose
Dose: 12 g/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g/day, 1 times / day
Sources:
unhealthy, mean age 51 years
n = 34
Health Status: unhealthy
Condition: complicated bacteremia
Age Group: mean age 51 years
Sex: M+F
Population Size: 34
Sources:
Transaminases increased 18%
12 g/day 1 times / day multiple, intravenous
Studied dose
Dose: 12 g/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g/day, 1 times / day
Sources:
unhealthy, mean age 51 years
n = 34
Health Status: unhealthy
Condition: complicated bacteremia
Age Group: mean age 51 years
Sex: M+F
Population Size: 34
Sources:
Creatinine serum increased 3%
12 g/day 1 times / day multiple, intravenous
Studied dose
Dose: 12 g/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g/day, 1 times / day
Sources:
unhealthy, mean age 51 years
n = 34
Health Status: unhealthy
Condition: complicated bacteremia
Age Group: mean age 51 years
Sex: M+F
Population Size: 34
Sources:
Leukopenia 3%
12 g/day 1 times / day multiple, intravenous
Studied dose
Dose: 12 g/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g/day, 1 times / day
Sources:
unhealthy, mean age 51 years
n = 34
Health Status: unhealthy
Condition: complicated bacteremia
Age Group: mean age 51 years
Sex: M+F
Population Size: 34
Sources:
Rash 3%
12 g/day 1 times / day multiple, intravenous
Studied dose
Dose: 12 g/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g/day, 1 times / day
Sources:
unhealthy, mean age 51 years
n = 34
Health Status: unhealthy
Condition: complicated bacteremia
Age Group: mean age 51 years
Sex: M+F
Population Size: 34
Sources:
Blood sodium decreased 3%
Disc. AE
12 g/day 1 times / day multiple, intravenous
Studied dose
Dose: 12 g/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g/day, 1 times / day
Sources:
unhealthy, mean age 51 years
n = 34
Health Status: unhealthy
Condition: complicated bacteremia
Age Group: mean age 51 years
Sex: M+F
Population Size: 34
Sources:
Leukopenia 3%
Disc. AE
12 g/day 1 times / day multiple, intravenous
Studied dose
Dose: 12 g/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g/day, 1 times / day
Sources:
unhealthy, mean age 51 years
n = 34
Health Status: unhealthy
Condition: complicated bacteremia
Age Group: mean age 51 years
Sex: M+F
Population Size: 34
Sources:
Rash 3%
Disc. AE
12 g/day 1 times / day multiple, intravenous
Studied dose
Dose: 12 g/day, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g/day, 1 times / day
Sources:
unhealthy, mean age 51 years
n = 34
Health Status: unhealthy
Condition: complicated bacteremia
Age Group: mean age 51 years
Sex: M+F
Population Size: 34
Sources:
PubMed

PubMed

TitleDatePubMed
Incidence of Chlamydia trachomatis and other potential pathogens in neonatal conjunctivitis.
2001
Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children.
2001
[Evaluation of MRSA identification with latex agglutination kit for the detection of penicillin-binding protein 2].
2001
[Monitoring of uropathogens and their susceptibility to antibiotics].
2001
Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program.
2001 Aug
Oxacillin susceptibility testing of Staphylococcus saprophyticus using disk diffusion, agar dilution, broth microdilution, and the Vitek GPS-105 card.
2001 Aug
[Coagulase negative staphylococci isolated on blood cultures].
2001 Aug
Multi-resistance to antimicrobial agents for the ten most frequently isolated bacterial pathogens.
2001 Aug
Therapeutic options for Gram-positive infections.
2001 Dec
Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model.
2001 Dec
Evaluation of a reverse hybridization blot test for detection of oxacillin-resistant Staphylococcus aureus.
2001 Dec
Natural antibiotic susceptibility of strains of the Enterobacter cloacae complex.
2001 Dec
Susceptibility of Arcobacter butzleri isolates to 23 antimicrobial agents.
2001 Dec
Crystallization and preliminary X-ray study of OXA-1, a class D beta-lactamase.
2001 Dec
A microdilution plating method for population analysis of antibiotic-resistant staphylococci.
2001 Fall
Low prevalence of methicillin-resistant strains among Staphylococcus aureus colonizing young and healthy members of the community in Portugal.
2001 Fall
Susceptibility of bacterial isolates to cefepime in comparison to other broad spectrum antimicrobial agents at a tertiary care center in Lebanon.
2001 Jan-Feb
RU-79115 (Aventis Pharma).
2001 Jun
Evaluation of the MRSA-Screen Test in detecting oxacillin resistance in community and hospital isolates of Staphylococcus aureus.
2001 Nov
Microbiology of normal external auditory canal.
2001 Nov
A sequence variant of Staphylococcus hominis with a high prevalence of oxacillin and fluoroquinolone resistance.
2001 Nov
Molecular characterization of a chromosomal locus in Staphylococcus aureus that contributes to oxidative defence and is highly induced by the cell-wall-active antibiotic oxacillin.
2001 Nov
Antimicrobial susceptibility of staphylococci isolated from the faeces of wild turkeys (Meleagris gallopavo).
2001 Nov
Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate.
2001 Nov
Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection.
2001 Nov-Dec
Vancomycin-intermediate Staphylococcus aureus in a home health-care patient.
2001 Nov-Dec
In vitro susceptibility of gram-positive cocci isolated from skin and respiratory tract to azithromycin and twelve other antimicrobial agents.
2001 Oct
Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides.
2001 Oct
Antibacterial action of several tannins against Staphylococcus aureus.
2001 Oct
Streptococcal meningitis in adults: therapeutic outcomes and prognostic factors.
2001 Oct
[Decreasing susceptibility to vancomycin in isogenic Staphylococcus aureus strains isolated from a single patient].
2001 Oct 13
Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates.
2001 Sep
Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.
2001 Sep
The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands.
2001 Sep
[Evaluation of the E-test and the ATB-PNEUMo battery for determining the beta-lactam MIC for Streptococcus pneumoniae in daily practice].
2001 Sep
Staphylococcus lugdunensis: an emerging cause of ventriculoperitoneal shunt infections.
2001 Sep
Determination of benzylpenicillin, oxacillin, cloxacillin, and dicloxacillin in cows' milk by ion-pair high-performance liquid chromatography after precolumn derivatization.
2001 Sep
Staphylococcus aureus in lower respiratory infections: clinical relevance of antimicrobial resistance.
2001 Sep
Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure.
2001 Sep
Epigallocatechin gallate synergy with ampicillin/sulbactam against 28 clinical isolates of methicillin-resistant Staphylococcus aureus.
2001 Sep
A comparison of PCR detection of mecA with two standard methods of oxacillin disk susceptibility testing for coagulase-negative staphylococci.
2002 Jan
Natural antibiotic susceptibility and biochemical profiles of Yersinia enterocolitica-like strains: Y. bercovieri, Y. mollaretii, Y. aldovae and 'Y. ruckeri'.
2002 Jan
Prediction of mecA-positive coagulase-negative staphylococci: assessment of different phenotypic methods, breakpoints, culture media and culture conditions.
2002 Jan
An outbreak of community-acquired foodborne illness caused by methicillin-resistant Staphylococcus aureus.
2002 Jan
Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999.
2002 Jan
Surveillance for antimicrobial resistance in Croatia.
2002 Jan
Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials.
2002 Jan 1
Simultaneous detection of the mecA and ileS-2 genes in coagulase-negative staphylococci isolated from Brazilian hospitals by multiplex PCR.
2002 Mar
A European study on the relationship between antimicrobial use and antimicrobial resistance.
2002 Mar
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
2002 Mar
Patents

Sample Use Guides

Oxacillin Injection, USP supplied as a premixed frozen solution is to be administered as a continuous or intermittent intravenous infusion. The usual dose recommendation is as follows: Adults 250-500 mg I.V. every 4-6 hours (mild to moderate infections) 1 gram I.V. every 4-6 hours (severe infections)
Route of Administration: Intravenous
Minimum inhibitory concentration that inhibited 90% of the coagulase-negative staphylococci isolates from bovine clinical and subclinical mastitis tested was 0.38 ug/ml for oxacillin
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:03:15 UTC 2021
Edited
by admin
on Sat Jun 26 02:03:15 UTC 2021
Record UNII
UH95VD7V76
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXACILLIN
INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
OXACILINA
Brand Name English
OXACILLIN [MI]
Common Name English
OXACILLIN [MART.]
Common Name English
OXACILLIN [VANDF]
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3,3-DIMETHYL-6-(((5-METHYL-3-PHENYL-4-ISOXAZOLYL)CARBONYL)AMINO)-7-OXO-,(2S,5R,6R)-
Common Name English
OXAZOCILLINE
Common Name English
OXACILLIN [WHO-DD]
Common Name English
OXACILLIN [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ01CF04
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000011281
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000011281
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
WHO-VATC QG51AG04
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000175497
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
WHO-ATC J01CF04
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000011281
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000011281
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000011281
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
LIVERTOX 717
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NCI_THESAURUS C1500
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000011281
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000011281
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000011281
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
WHO-VATC QJ51CF04
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
NDF-RT N0000011281
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
Code System Code Type Description
RXCUI
7773
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C62063
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
EPA CompTox
66-79-5
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
MESH
D010068
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
EVMPD
SUB09484MIG
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL819
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
DRUG CENTRAL
2006
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
FDA UNII
UH95VD7V76
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
WIKIPEDIA
OXACILLIN
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
DRUG BANK
DB00713
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
PUBCHEM
6196
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
INN
1372
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-635-5
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
CAS
66-79-5
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
MERCK INDEX
M8273
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY Merck Index
LACTMED
Oxacillin
Created by admin on Sat Jun 26 02:03:15 UTC 2021 , Edited by admin on Sat Jun 26 02:03:15 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC